Literature DB >> 34273059

Exosomal noncoding RNAs: key players in glioblastoma drug resistance.

Ahmad Movahedpour1,2, Seyyed Hossein Khatami3, Marjan Khorsand4, Mahsa Salehi5, Amir Savardashtaki1,6, Seyedeh Habibeh Mirmajidi1, Babak Negahdari5, Nezhat Khanjani7, Parisa Naeli8, Omid Vakili9, Mortaza Taheri-Anganeh10,11.   

Abstract

Glioma, as one of the most severe human malignancies, is defined as the Central Nervous System's (CNS) tumors. Glioblastoma (GBM) in this regard, is the most malignant type of gliomas. There are multiple therapeutic strategies to cure GBM, for which chemotherapy is often the first-line treatment. Still, various cellular processes, such as uncontrolled proliferation, invasion and metastasis, may disturb the treatment efficacy. Drug resistance is another process in this way, which can also cause undesirable effects. Thereupon, identifying the mechanisms, involved in developing drug resistance and the relevant mechanisms can be very helpful in GBM management. The discovery of exosomal non-coding RNAs (ncRNAs), RNA molecules that can be transferred between the cells and different tissues using the exosomes, was a milestone in this regard. It has been revealed that the key exosomal ncRNAs, including circular RNAs, microRNAs, and long ncRNAs, are able to modulate GBM drug resistance through different signaling pathways or by affecting regulatory proteins and their corresponding genes. Nowadays, researchers are trying to overcome the limitations of chemotherapy by targeting these RNA molecules. Accordingly, this review aims to clarify the substantial roles of exosomal ncRNAs in GBM drug resistance and involved mechanisms.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Drug resistance; Exosomes; Glioblastoma; Noncoding RNAs

Mesh:

Substances:

Year:  2021        PMID: 34273059     DOI: 10.1007/s11010-021-04221-2

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  103 in total

1.  CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012.

Authors:  Quinn T Ostrom; Haley Gittleman; Jordonna Fulop; Max Liu; Rachel Blanda; Courtney Kromer; Yingli Wolinsky; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2015-10-27       Impact factor: 12.300

2.  Glioblastoma incidence rate trends in Canada and the United States compared with England, 1995-2015.

Authors:  Faith G Davis; Trenton R Smith; Haley R Gittleman; Quinn T Ostrom; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2020-02-20       Impact factor: 12.300

Review 3.  Mechanisms of immunotherapy resistance: lessons from glioblastoma.

Authors:  Christopher M Jackson; John Choi; Michael Lim
Journal:  Nat Immunol       Date:  2019-07-29       Impact factor: 25.606

Review 4.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

5.  Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.

Authors:  James R Perry; Normand Laperriere; Christopher J O'Callaghan; Alba A Brandes; Johan Menten; Claire Phillips; Michael Fay; Ryo Nishikawa; J Gregory Cairncross; Wilson Roa; David Osoba; John P Rossiter; Arjun Sahgal; Hal Hirte; Florence Laigle-Donadey; Enrico Franceschi; Olivier Chinot; Vassilis Golfinopoulos; Laura Fariselli; Antje Wick; Loic Feuvret; Michael Back; Michael Tills; Chad Winch; Brigitta G Baumert; Wolfgang Wick; Keyue Ding; Warren P Mason
Journal:  N Engl J Med       Date:  2017-03-16       Impact factor: 91.245

6.  The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.

Authors:  James J Vredenburgh; Annick Desjardins; David A Reardon; Katherine B Peters; James E Herndon; Jennifer Marcello; John P Kirkpatrick; John H Sampson; Leighann Bailey; Stevie Threatt; Allan H Friedman; Darell D Bigner; Henry S Friedman
Journal:  Clin Cancer Res       Date:  2011-04-29       Impact factor: 12.531

Review 7.  Adult Glioblastoma.

Authors:  Brian M Alexander; Timothy F Cloughesy
Journal:  J Clin Oncol       Date:  2017-06-22       Impact factor: 44.544

Review 8.  Molecular targeted therapy of glioblastoma.

Authors:  Emilie Le Rhun; Matthias Preusser; Patrick Roth; David A Reardon; Martin van den Bent; Patrick Wen; Guido Reifenberger; Michael Weller
Journal:  Cancer Treat Rev       Date:  2019-09-11       Impact factor: 12.111

9.  Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.

Authors:  Roger Stupp; Sophie Taillibert; Andrew A Kanner; Santosh Kesari; David M Steinberg; Steven A Toms; Lynne P Taylor; Frank Lieberman; Antonio Silvani; Karen L Fink; Gene H Barnett; Jay-Jiguang Zhu; John W Henson; Herbert H Engelhard; Thomas C Chen; David D Tran; Jan Sroubek; Nam D Tran; Andreas F Hottinger; Joseph Landolfi; Rajiv Desai; Manuela Caroli; Yvonne Kew; Jerome Honnorat; Ahmed Idbaih; Eilon D Kirson; Uri Weinberg; Yoram Palti; Monika E Hegi; Zvi Ram
Journal:  JAMA       Date:  2015-12-15       Impact factor: 56.272

10.  Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the elderly: a meta-analysis.

Authors:  An-an Yin; Lu-hua Zhang; Jin-xiang Cheng; Yu Dong; Bo-lin Liu; Ning Han; Xiang Zhang
Journal:  PLoS One       Date:  2013-09-24       Impact factor: 3.240

View more
  7 in total

Review 1.  Gastrointestinal cancer drug resistance: the role of exosomal miRNAs.

Authors:  Mahsa Salehi; Asma Vafadar; Seyyed Hossein Khatami; Mortaza Taheri-Anganeh; Omid Vakili; Amir Savardashtaki; Babak Negahdari; Parisa Naeli; Hamid Behrouj; Hassan Ghasemi; Ahmad Movahedpour
Journal:  Mol Biol Rep       Date:  2021-11-30       Impact factor: 2.316

Review 2.  Alterations in Molecular Profiles Affecting Glioblastoma Resistance to Radiochemotherapy: Where Does the Good Go?

Authors:  Juliana B Vilar; Markus Christmann; Maja T Tomicic
Journal:  Cancers (Basel)       Date:  2022-05-13       Impact factor: 6.575

Review 3.  Current Understanding of Exosomal MicroRNAs in Glioma Immune Regulation and Therapeutic Responses.

Authors:  Jinwu Peng; Qiuju Liang; Zhijie Xu; Yuan Cai; Bi Peng; Jianbo Li; Wenqin Zhang; Fanhua Kang; Qianhui Hong; Yuanliang Yan; Mingyu Zhang
Journal:  Front Immunol       Date:  2022-01-14       Impact factor: 7.561

4.  Extracellular Vesicles Secreted by Glioma Stem Cells Are Involved in Radiation Resistance and Glioma Progression.

Authors:  Chenkai Ma; Hong P T Nguyen; Jordan J Jones; Stanley S Stylli; Clarissa A Whitehead; Lucy Paradiso; Rodney B Luwor; Zammam Areeb; Eric Hanssen; Ellie Cho; Ulrich Putz; Andrew H Kaye; Andrew P Morokoff
Journal:  Int J Mol Sci       Date:  2022-03-02       Impact factor: 5.923

Review 5.  Recent insights into the microRNA-dependent modulation of gliomas from pathogenesis to diagnosis and treatment.

Authors:  Alireza Mafi; Atefe Rahmati; Zahra Babaei Aghdam; Raziyeh Salami; Marziyeh Salami; Omid Vakili; Esmat Aghadavod
Journal:  Cell Mol Biol Lett       Date:  2022-08-03       Impact factor: 8.702

6.  Radiated glioblastoma cell-derived exosomal circ_0012381 induce M2 polarization of microglia to promote the growth of glioblastoma by CCL2/CCR2 axis.

Authors:  Chunzhi Zhang; Yuan Zhou; Ya Gao; Ze Zhu; Xianliang Zeng; Weizi Liang; Songwei Sun; Xiuli Chen; Hu Wang
Journal:  J Transl Med       Date:  2022-09-04       Impact factor: 8.440

7.  Kill two birds with one stone: Engineered exosome-mediated delivery of cholesterol modified YY1-siRNA enhances chemoradiotherapy sensitivity of glioblastoma.

Authors:  Xiao Liu; Zhengcong Cao; Nannan Liu; Guangxun Gao; Mingrui Du; Yingwen Wang; Boyang Cheng; Maorong Zhu; Bo Jia; Luxiang Pan; Wangqian Zhang; Yuran Jiang; Wei He; Linlin Xu; Wei Zhang; Qunxing An; Qingdong Guo; Jintao Gu
Journal:  Front Pharmacol       Date:  2022-08-19       Impact factor: 5.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.